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Abstract 
A high-throughput, automated screening platform has been developed for the assessment 
of biological membrane damage caused by nanomaterials. Membrane damage is detected 
using the technique of analysing capacitance-current peak changes obtained through 
rapid cyclic voltammetry (RCV) measurements of a phospholipid self-assembled 
monolayer, formed on a mercury film deposited onto a microfabricated platinum 
electrode, after the interaction of a biomembrane-active species. To significantly improve 
wider usability of the screening technique, a compact, high-throughput screening 
platform was designed, integrating the monolayer-supporting microfabricated electrode 
into a microfluidic flow cell, with bespoke pumps used for precise, automated control of 
fluid flow. Chlorpromazine, a tricyclic antidepressant, and citrate-coated 50 nm diameter 
gold nanomaterial (AuNM) were screened to successfully demonstrate  ǯ 
viability for high-throughput screening. Chlorpromazine and AuNM showed interactions 
with a 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) monolayer at concentrations in 
excess of  ?Ɋ-3. Biological validity of the electrochemically-measured interaction 
of chlorpromazine with DOPC monolayers was confirmed through quantitative 
comparisons with HepG2 and A549 cytotoxicity assays. The platform also demonstrated 
desirable performance for high-throughput screening, with membrane interactions 
detected in <6 min per assay. Automation contributed to this significantly, by reducing 
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the required operating skill level when using the technique and minimising fluid 
consumption.  
 
Keywords 
Phospholipid monolayer, gold nanomaterial, biomembrane interaction, microfluidic flow 
cell, mercury electrode, rapid cyclic voltammetry, high-throughput screening 
 
1. Introduction 
Advances in nanotechnology have resulted in widespread usage of nanomaterials, often 
with applications in consumer products, biomedical and sensing technologies [1-4]. 
However, toxicity hazards associated with nanomaterials have been widely reported, 
with growing research in the field of nanotoxicology emphasising the need for screening 
techniques to characterise nanomaterial hazards [5-12]. As the applications for 
engineered nanomaterials continues to grow, high-throughput, in vitro screening 
solutions are essential to accelerate the process of evaluating the toxicity of novel 
engineered nanomaterials and to meet the demand for hazard identification [13, 14]. 
High-throughput in vitro toxicity sensing technologies also provide an alternative to in 
vivo animal toxicity studies, which have ethical implications and are not economically 
feasible for screening a vast range of nanomaterials [3, 15, 16].  
Understanding cytotoxicity remains a particularly important and significant challenge in 
the field of nanotoxicology, as nanomaterials, due to their small size, can have unique 
properties that influence the mechanisms of interaction with cell membranes [17]. 
Engineered nanomaterials can interact with cell membranes through adsorption onto the 
membrane, penetration through the membrane and endocytosis [17-21]. The 
understanding of nanomaterial cytotoxicity is challenging due to the complexity of cell 
membranes and the wide range of nanomaterial parameters, such as particle size, 
material and shape, that can influence the mechanisms of membrane interaction [5, 7, 10, 
11, 17, 21]. Cell-based in vitro toxicity assays are typically employed for the assessment 
of nanomaterial cytotoxicity, which are adapted for high-throughput screening through 
the use of high quantity multi-well plate platforms [22-24]. However, generally there 
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remains a lack of high-throughput techniques for in vitro assessment of nanomaterial 
hazards.  
One solution to rapid screening of the interaction of nanomaterial with biological 
membranes is the application of a membrane-on-chip sensing technique, one of which 
measures an electrochemical response to detect interaction with a phospholipid, self-
assembled monolayer supported on a mercury (Hg) electrode [25-35]. This has been 
well-established as an effective technique for quantifying and mechanistically 
understanding biomembrane interaction. The interaction with the monolayer is 
evaluated through highly sensitive and rapidly detectable changes in capacitance-current 
peaks after the interaction of a biomembrane-active compound or particle with the Hg-
supported monolayer, measured through the application of rapid cyclic voltammetry 
(RCV). A strong correlation exists between biomembrane interaction measured using the 
monolayer technique and physical membrane damage of a more complex biological 
bilayer membrane, confirmed through direct comparison with phospholipid unilamellar 
vesicle studies [21, 36].  
Recently, the technique has been improved through the use of a microfabricated 
electrode, consisting of platinum (Pt) discs on to which Hg can be deposited to support 
the phospholipid monolayer [25, 26], as opposed to a hanging Hg drop electrode used in 
original studies by Nelson [28], enabling safe and robust use of Hg as a working electrode 
in a flow environment. Another significant advantage of this is that the phospholipid 
monolayer can be rapidly re-established after measurement to create a reusable 
electrode, ideal for high-throughput screening. This is advantageous compared to other 
high-throughput in vitro methods, such as high quantity, multi-well plate cell-based 
assays, which require a longer time period to obtain meaningful results [14, 23]. This also 
reduces the possibility of nanomaterial transformations (e.g. aggregation) during 
assessment, which have been reported to contribute to ambiguity in cell assay studies 
[37-39]. However, despite robust characterisation and validation of the sensing 
technique [40], limitations still exist, such as a complex operating procedure and 
excessive fluid consumption, preventing its wider adoption for high-throughput hazard 
assessment of nanomaterials.  
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With advances in microfluidic flow cell technology and the possibility to automate 
processes, significant potential exists to improve the current screening methodology, as 
most recently described by Vakurov et al. [7], to reduce fluid consumption, increase 
throughput and improve usability. Microfluidic flow cells offer significant benefits for 
high-throughput biosensing applications, by reducing fluid consumption in a low cost and 
easy to manufacture, high precision cell [41-47]. The application of microfluidic 
technology is particularly advantageous for nanomaterial toxicity screening, enabling 
consistent transport of nanomaterial in high precision laminar fluid flow and being well-
suited for automation [16]. Automation of the sensing technique also offers the potential 
to reduce required operator skill level by simplifying the screening process. 
This study details the development of a new automated screening platform, 
incorporating a microfluidic flow cell, containing an Hg-supported membrane monolayer, 
for high-throughput sensing of nanomaterial-biomembrane interactions. The new 
screening platform offers a significant enhancement on the previous generations of the 
biomembrane-sensing system to create a rapid, high-throughput sensor viable for in vitro 
screening of nanomaterial-membrane interaction, decreasing required operator skill 
levels and decreasing fluid consumption. Gold nanomaterial (AuNM) and 
chlorpromazine, a pharmaceutical compound, were screened using the screening 
platform to demonstrate its viability as a high-throughput sensor for assessing 
biomembrane interactions of nanomaterial and to prove equivalence to well-validated 
studies using the sensing technique.  
 
2. Automated Screening Platform Design 
 
2.1. Overview of Screening Technique 
A schematic of the sensing technique is provided in Figure 1 to demonstrate how 
biomembrane activity is assessed through RCV analysis. After supporting the 
phospholipid monolayer onto a Hg electrode, the characteristic RCV response consists of 
two capacitance-current peaks on the forward and reverse scans when the phospholipid 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) is used [40]. A biomembrane-active 
species (e.g. nanoparticles) can adsorb to and/or penetrate the monolayer, during flow 
across the coated electrode, suppressing the capacitance-current and/or shifting the 
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potential of peaks measured using RCV. The first capacitance-current peak on the 
forward scan, labelled ǮAǯ in Figure 1, is often of significant interest to the operator and 
this peak is used to provide a quantitative indication of a species interaction with the 
monolayer. The capacitance current peak represents a monolayer phase change  
corresponding to  ingress of electrolyte into the phospholipid monolayer [28, 40].  
 
Figure 1: Schematic of the screening technique to evaluate biomembrane interaction of 
nanomaterial with an Hg-supported phospholipid membrane monolayer through analysis 
of a RCV response ?ǁŝƚŚƉĞĂŬ ? ?ŚŝŐŚůŝŐŚƚŝŶŐƚŚĞĐĂƉĂĐŝƚĂŶĐĞ-current peak used to 
provide a quantitative comparison of biomembrane interaction 
The aim of the automated platform design was to utilise this well-established sensing 
technique and create an easy-to-use, high-throughput, in vitro sensing platform for rapid 
screening of nanomaterials. A critical analysis of the previous state of the technology (the 
methodology as described by Vakurov et al. [7]) was completed to identify limitations of 
the method, leading to the following objectives being set as criteria for the screening 
platform design. These objectives will enable wider potential use of the technique for 
assessment of nanomaterial hazards: 
i. The screening process was to be automated, thus significantly decreasing the 
complexity of the screening procedure and improving repeatability of the system 
to enable an inexperienced operator to use the screening system reliably and with 
minimal guidance. 
ii. The time required to screen nanomaterials was to be reduced, thus improving 
throughput and enhancing the feasibility of the technique for screening vast 
quantities of nanomaterials. 
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iii. The screening platform was to be compactly designed, avoiding the use of large 
and numerous components to reduce space requirements and enable the device 
to be portable, improving feasibility of the design as a single screening platform. 
iv. A graphical user interface was to be developed to simplify control of the system, 
making the system easy-to-use for inexperienced operators, requiring minimal 
control to complete the screening process and therefore contributing to improved 
throughput. 
v. Fluid consumption and waste was to be reduced by optimising flow rates and 
volumes consumed through automation and reducing tubing usage to make the 
technique more viable for screening vast quantities of nanomaterial. 
The newly-developed automated screening platform is shown in Figure 2, consisting of a 
microfluidic flow cell containing the phospholipid monolayer supported on a Hg sensing 
electrode, four automated bespoke syringe pumps enabling storage and transportation 
of fluids (electrolyte, test sample, phospholipid and water) into the flow cell, a field-
programmable gate array (FPGA) data acquisition and control unit used to interface 
between software and hardware and an ACM Research Potentiostat for electrochemical 
measurements. A laptop was connected to control the screening platform, interfacing 
with syringe pumps and the FPGA control unit. The components of the platform are 
discussed in more detail in the following sections.  
 
Figure 2: Automated platform used for electrochemical analysis of biomembrane activity 
of compounds and particles after interaction with an Hg-supported phospholipid 
monolayer, consisting of a microfluidic flow cell, four syringe pumps, an FPGA data 
acquisition and control unit and a potentiostat, where RE is the reference electrode, CE is 
the counter electrode and WE is the working electrode 
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2.2. Microfluidic Flow Cell and Sensing Electrode 
A microfluidic flow cell was designed to transport fluids consumed in the screening 
process to the sensing electrode, contained within the flow cell, for electrochemical 
analysis. A layered approach was used for the microfluidic flow cell design, with flow cell 
layers fabricated using a laser cutter. This allows an inherently 3D structure to be 
established with the ability to seal ancillary components into the flow cell. Cast 
poly(methyl methacrylate) (PMMA) was employed for harder layers of the flow cell and 
Pt-cured silicone sheet was used for softer layers. The flow cell components were 
fastened together using bolts to provide a compression seal between softer and harder 
layers to prevent leakage of fluids and enable electrochemical measurements, by isolating 
electrical connections from contact with electrolyte. The design is both robust and 
provides excellent sealing. 
The microfluidic flow cell is shown in Figure 3. The main components of the design 
include (1) a ceramic junction screw-type silver/silver chloride (Ag/AgCl) reference 
electrode containing 3 M NaCl gel (ALS); (2, 5 and 8) PMMA layers; (3) a 25 mm long Pt 
rod with 3.0 mm diameter (Goodfellow), used as the counter electrode, mounted in the 
flow cell downstream of the working electrode using a flangeless nut and ferrule; (4, 6 
and 8) silicone layers to channel fluids through the flow cell and/or seal the flow cell and 
(7) a microfabricated Pt/Hg sensing electrode (supplied by Tyndall National Institute, 
Ireland). The Pt/Hg electrode consisted of eight Pt discs (12), with radii of 0.48 mm (of 
which two discs were deposited with Hg prior to insertion in the flow cell). Silicon nitride-
insulated electrical contacts enabled potentiostat connection to the Pt/Hg electrode (13). 
Fluids were transported into and out of the flow cell with a  ?Ȁ ? ?ǳǡ ?Ȁ ?ǳ
outer diameter, fluorinated ethylene propylene (FEP) tubing, mounted in the inlet and 
outlet ports on the flow cell (layer 2) through the use of standard fittings (¼-28 Unified 
National Fine (UNF) flangeless threaded nuts). FEP tubing was used for chemical 
resistance and compatibility with test compounds and particles to prevent 
contamination. Fluids were transported out of the flow cell and into a waste container. 
Syringes containing test fluids were connected to tubing via a two-way shut off valve, 
closed to prevent air bubbles from entering the system when replacing syringes. The 
tubing from each syringe was connected to a polyether ether ketone cross component, to 
mix fluids prior to the flow cell inlet.  
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Nanomaterial transport through microfluidic flow cells provides an additional design 
challenge, with some microfluidic devices reported to have been ineffective at 
transporting nanomaterials to sensing areas and cell assay well plates [47]. Challenges 
with microfluidic design for nanomaterial transport include ensuring no aggregation, 
minimising entrapment, preventing air bubbles and decreasing sedimentation of 
nanomaterial in fluid tubing [16]. Aggregation and sedimentation of nanomaterial was 
minimised by using short tubing lengths. Nanomaterial was mixed with electrolyte flow 
just prior to the flow cell inlet, rather than further upstream, to minimise the possibility 
of aggregation. Measurements were completed in continuous flow, also decreasing 
potential time for aggregation of nanomaterial. Entrapment of nanomaterial was not 
observed as a result of minimising the number of components in the fluid flow path. 
Whilst appearing mechanically complex, from a flow perspective the flow channel within 
the flow cell is simple. Critically the dead spaces around ancillary components (e.g. the 
reference and counter electrodes and piping connections) were minimal reducing the 
chance of entrapment of nanomaterial and therefore reducing demand in cleaning 
between subsequent measurements. Nanomaterial was easily flushed through and 
removed from the system during cleaning, confirmed by the RCV response. 
To confirm the flow cell effectively transported species to the sensing electrode, as 
highlighted in Figure 3, and to confirm no undesirable flow conditions (such as flow 
recirculation as the flow channel width expands [48, 49]) influenced transport to the 
sensing electrode, computational fluid dynamics (CFD) simulations using COMSOL 
Multiphysics 5.3a [50] were completed to predict species transport through the flow 
channel after solving a finite element discretisation of the Navier-Stokes equations for 
laminar fluid. Full details of the methodology used to complete these simulations are 
provided in the Supplementary Material.  
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Figure 3: Microfluidic flow cell showing (a) exploded assembly of components, (b) cross-
section schematic of the flow cell, (c) top view of the flow cell assembly and (d) 
microfabricated sensing Pt/Hg electrode, consisting of (1) Ag/AgCl reference electrode, (2) 
PMMA top plate, (3) Pt rod counter electrode, (4) silicone fluid inlet/outlet layers, (5) 
PMMA flow channel layer, (6) silicone sensing layer, (7) microfabricated sensing Pt/Hg 
electrode, (8) silicone layers for electrode support and sealing, (9) PMMA bottom layer, 
(10) screw holes x 6 to mount and seal flow cell, (11) screw holes x 4 to mount sealed flow 
cell on aluminium breadboard, (12) Pt working electrode and (13) electrical contacts, 
sealed from the electrolyte, for potentiostat connection 
 
2.3. User Control Interface 
An easy-to-use graphical user interface, shown in the Supplementary Material, was 
developed in LabVIEW to enable operator control of the screening platform and to 
display relevant information to the operator. The user interface consisted of operator 
controls to specify the size of the syringe used and the volume of fluid contained in the 
syringe for electrolyte, lipid, screening test sample and water; operator controls to 
specify the fluid flow rates and potentials for RCV measurements and the RCV response 
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from which data could be easily extracted. An FPGA data acquisition and control unit 
controlled the potentials applied by the potentiostat, as determined by the operator on 
the user interface, and acquired the resulting electrochemical data, presented on the user 
interface. This enabled the operator to screen nanomaterials with minimal effort, 
switching between the different processes of the screening procedure with ease, 
significantly reducing the time required to complete a screening programme. 
 
3. Experimental 
 
3.1. Materials 
AuNM and chlorpromazine were screened to assess interaction with the Hg-supported 
phospholipid monolayer. The phospholipid used was DOPC, a common component of 
biological membranes, purchased as 99% pure (Avanti Polar Lipids Alabaster, AL).  A 
minimum dispersion of 0.5 mmol dm ?3 of DOPC with Milli-  ȋ ? ?Ǥ ? ȳȌ 
prepared and mixed by gently shaking. The control electrolyte was 0.1 mol dm ?3 KCl 
(calcined at 600°C for 2 h) and buffered at pH 7.4 with 0.01 mol dm ?3 phosphate ȋ    ǡ    Ǯǯ    
control interface).  
Chlorpromazine (Sigma-Aldrich), a tricyclic antidepressant with the compound 
molecular structure shown in the Supplementary Material, has been regularly screened 
and shown to be highly biomembrane-active in previous studies using the RCV 
phospholipid monolayer membrane-on-chip technique [25, 26]. Therefore, interactions 
of chlorpromazine with the monolayer were assessed to confirm the validity of results 
measured using the new platform at concentrations ranging from 10 ?5 to 104 Ɋ ?3. 
Chlorpromazine was also used for comparison with cytotoxicity assays to confirm 
biological relevance of the electrochemically-measured membrane interactions through 
cell viability studies.  
Dispersions of citrate-coated AuNM (Alfa Aesar) with a diameter of 50 nm were screened 
in a concentration range from 10 ?3 to 102 Ɋ ?3 to evaluate the RCV response after 
interaction with the Hg-supported DOPC monolayer and to demonstrate the performance 
of the platform as a viable solution to high-throughput in vitro screening of 
nanomaterials. AuNMs have been shown, in some cases, to be cytotoxic, potentially as a 
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result of cell membrane penetration [11, 51], so were chosen to be investigated in this 
study to demonstrate interaction with a DOPC membrane. The dispersion of AuNM was 
reported as a concentration of Ɋ  ?3 of Au in the dispersion, confirmed by 
inductively coupled plasma mass spectrometry (PerkinElmer SCIEX ELAN DRC-e with a 
PerkinElmer S10 auto sampler) after digestion of known volumes of AuNM, from the 
citrate-coated AuNM stock dispersion, in aqua regia. By determining elemental 
concentration of Au using this technique, the appropriate volume of AuNM was dispersed 
in Milli-Q water to achieve the Au concentrations reported. 
The size of the AuNM was confirmed using dynamic light scattering (DLS) measurements 
on a Malvern Instruments nanoZS Zetasizer prior to the test by dispersing the AuNM in a 
Milli-Q water medium, showing an average particle diameter of 68 nm, based on intensity 
plots vs particle diameter in Figure 4. To confirm that aggregation of the AuNM would not 
be significant after the dispersion mixed with PBS during flow through the flow cell, 
AuNM was dispersed in PBS and DLS measurements were completed after 5 min and 20 
min of incubation, with all AuNM expected to flow through the flow cell within 1 min of 
mixing with PBS during screening tests. No aggregation was measured during that period, 
as shown in Figure 4 by equivalent size distribution observed between the AuNM 
samples. A scanning electron microscope (SEM) was used to image the AuNM, showing 
the approximate size and shape of the AuNM used in the study in Figure 4. Images were 
obtained by drying an AuNM dispersion on an SEM stub and using an FEI Nova NanoSEM 
450 at an operating voltage of 5 kV in the concentric back scattering mode. 
To prepare the microfabricated electrode, prior to insertion in the flow cell, it was cleaned 
in Piranha solution for approximately 15 min, rinsed with Milli-Q water and dried. After 
cleaning, Hg was deposited onto two Pt bases prior to mounting in the flow cell.  Once 
contained within the flow cell, an RCV potential  ?0.4 V to  ?3.0 V at a scan 
rate of 100 V s ?1 was completed, for approximately 30 min, maintained under PBS 
throughout this period in static conditions to ensure robust adhesion of the Hg to the Pt 
substrate was achieved and any organic material from the Hg surface was removed. A 
more detailed method for preparation of the microfabricated Pt/Hg electrode is provided 
by Rashid et al. [32].  
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Figure 4: (a) Intensity plot from DLS measurements of particle size distribution for AuNM 
dispersions in Milli-Q water and PBS, showing average particle diameter of 68 nm and no 
aggregation within 20 minutes in PBS (where time in min is the time at the end of 
completed measurements), (b) an SEM image of the size distribution of AuNM and (c) a 
higher magnification SEM image showing the approximate size of AuNM used in the study 
 
3.2. Screening Methodology Ȃ Automated Platform 
The fluids used during the screening procedure (PBS, DOPC and sample) were prepared 
prior to testing by bubbling with argon gas, for a minimum period of 30 min prior to 
screening, to exclude dissolved oxygen (O2) in the fluids. After excluding O2, individual 
syringes were filled, mounted on the platform and connected to the tubing. RCV scans 
were completed by applying potential excursions between two potentials at a specified 
scan rate, depending on the stage of the screening procedure. The four stages, controlled 
from the user interface as shown in the Supplementary MaterialǡǮǯǡǮǯǡǮǯǮǯǤ 
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3.2.1. Idle Response Ǯǯ ?0.4 V to  ?1.2 V was completed at a scan 
rate of 40 V s ?1 in static conditions, so the RCV response could be analysed after each 
stage of the process. No fluid was flushed into the flow cell during this stage to allow for 
analysis of the RCV response. An appropriate control RCV response, prior to sample 
injection, could be confirmed by the operator and the resulting change in the RCV 
response after the sample was injected could be analysed. Data was exported from the ǮIdleǯ stage, where RCV responses were exported for further analysis.  
 
3.2.2. Flow Cell Clean Ǯǯǡ ?0.4 V to  ?3.0 V was completed at a scan 
rate of 100 V s ?1 under PBS flow at a constant flow rate of 4.0 cm3 min ?1 to flush any 
remaining sample (and other contaminants) out of the flow cell into a waste container. A 
minimum of 5 cm3 of buffer was used to clean the flow cell after each measurement. 
 
3.2.3. Supporting a Phospholipid Membrane Monolayer on Hg 
Once cleaned, DOPC was flushed into the flow cell at a flow rate of 1.0 cm3 min ?1 in the ǮǯǤ ? ?Ǥ ? ? Ǥ ? ? ? ?
V s ?1 under PBS flow at a constant flow rate of 4.0 cm3 min ?1, before retuǮǯ
stage to assess the RCV response. A total of 0.5 cm3 of DOPC was injected to create a stable 
monolayer on the Hg electrode, confirmed through analysis of the RCV response showing 
the characteristic peaks, specific to the phospholipid in use, at appropriate potentials 
[25].  
 
3.2.4. Sample Interaction with Phospholipid Membrane Monolayer 
To assess interaction with the DOPC layer, a test sample was flushed in during the Ǯǯ ?Ǥ ?cm3 min ?1 with PBS at a flow rate of 4.0 cm3 min ?1. A     ? ?Ǥ ?    ? ?Ǥ ?          ? ?   ?1, Ǯǯǡchanged in real-time during flow of 
sample through the flow cell. All sample concentrations were screened three times by 
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evaluating samples in order of increasing concentration, starting with the lowest 
concentration. Another three repeats were completed by screening samples in a random 
order, to ensure that results were not influenced by the order in which sample 
concentrations were screened. 
After completing a measurement, the syringe containing the test sample was cleaned with 
MilliQ water (or replaced if a significant interaction was observed). A total of 2 cm3 of PBS 
was also injected through the tubing connected to the sample syringe to flush any 
remaining sample through the tubing and into the waste container. The PBS, DOPC and 
sample syringes were replaced after all sample concentrations were screened, prior to 
completing repeat measurements. The flow cell was then Ǯǯ
process on the user interface to remove any remaining DOPC on the Pt/Hg electrode and 
flush out sample, re-establishing the Pt/Hg electrode as a clean sensor available for the 
next measurement.  
 
3.3. Screening Methodology Ȃ Predecessor System 
A comparison was made with the well-validated predecessor membrane-on-chip sensor, 
by screening the same samples on both systems. A detailed description of the system and 
methodology for its use is provided by Vakurov et al. [7]. Sample preparation was 
completed using the same methodology and the screening process was completed in the 
same order as for the automated platform using an identical electrochemical procedure. 
PBS was stored in a 0.5 dm3 reservoir on the manual system and transported to the flow 
cell using a peristaltic pump to maintain a flow rate of 4.67 cm3 min ?1. The total volume 
flow of PBS used to screen the compounds could not be precisely controlled. DOPC and 
samples were injected into the PBS flow manually using a syringe, upstream of the flow 
cell. For this reason, flow rates of DOPC and sample were not controlled and volumes of 
fluid flushed through the cell were not precisely known or consistent for all 
measurements. For electrochemical measurements a Ag/AgCl 3.5 mol dm ?3 KCl reference 
electrode was fitted into the flow cell. The counter electrode on the microfabricated 
electrode was used, with a much greater electrode area exposed in the manual system 
flow cell, due to a different flow cell design. An Autolab PGSTAT12 potentiostat was used 
for electrochemical measurements.  
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3.4. Cytotoxicity Assays 
To confirm equivalence between the automated RCV platform and well-established in 
vitro techniques, cell viability assays were performed with two widely used cell lines: 
HepG2 (human hepatocellular carcinoma cells) and A549 (alveolar epithelial cells), both 
purchased from Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH (cell line no. ACC-180 and ACC-107, Braunschweig, Germany). Both 
cell lines were cultured in Roswell Park Memorial Institute medium (RPMI1640, R8758, 
Sigma-Aldrich, Germany) supplemented with 10% v/v fetal bovine serum (FBS, 26140-
079 ThermoFisher Scientific, Germany), 100 U/ml penicilli ? ? ?ɊȀ
(5070-63, ThermoFisher Scientific, Germany) in a humidified incubator at 37 °C with 5% 
CO2 atmosphere. For the exposure with chlorpromazine, the cells were seeded at a 
density of 10,000 cells per well in a 96 well plate and cultured for 24 hours. The stock 
solution of chlorpromazine was freshly prepared for all experiments and diluted at the 
desired concentration in cell culture medium. Cell culture medium without chemical was 
used as negative control. The cells were exposed with chlorpromazine in doses ranging 
from 5 to 100 µmol dm-3 for 24 hours. The cell viability reagent alamarBlue (Invitrogen, 
Germany) was diluted 1:10 in fresh culture medium and incubated with the cells for 1 h 
at 37 °C. The fluorescence (excitation 530 nm, emission 590 nm) was determined and the 
values were blank corrected. The viability of the control cells was set to 100%. Three 
independent experiments were performed with each cell line and at least three single 
wells per test condition. 
 
4. Results and Discussion 
 
4.1. Simulation of Species Transport in Flow Cell 
The transport of chlorpromazine through the flow cell at a constant flow rate of 4.0 cm3 
min ?1 is shown in Figure 5, represented by the concentration (c) along the bottom surface, 
relative to the inflow concentration (cin) to confirm appropriate transport of the species 
to the sensing electrode. The average concentration of chlorpromazine over the 
approximate surface area of the electrodes on the Pt/Hg electrode was determined from 
the predictions and shown in Figure 5. The error bars plotted in Figure 5 represent the 
maximum and minimum concentration predicted over the surface area of the electrode 
16 
 
at a particular time. A concentration at the electrode equal to the desired inflow 
concentration (c/cin = 1.0) was achieved within approximately 15 s of flow through the 
flow cell, showing the flow cell design was effective.  
 
Figure 5: CFD simulations of time-dependent transport through the flow cell, showing the 
concentration (c) on the bottom of surface of the flow cell (i.e. the location of the 
electrode), relative to the inflow concentration (cin) of chlorpromazine under steady state 
flow through the flow cell at a flow rate of 4.0 cm3 minA?1 and showing the average 
concentration over the surface area of the electrode positioned 17.6 mm from the flow 
inlet 
 
4.2. Chlorpromazine 
The RCV scans for chlorpromazine interactions (red line) measured using the new 
automated platform are shown in Figure 6 and are compared against the DOPC baseline 
(black line) response. The scans for all concentrations are given in the Supplementary 
Material. No significant interaction between chlorpromazine and DOPC was observed at 
low concentrations, but at concentrations above 1 µmol dm ?3, a significant interaction 
was measured. The interactions caused suppression of the capacitance-current peaks, 
measured between potentials of  ?0.95 V and  ?1.05 V, which, at high concentrations, were 
completely suppressed. Suppression of the capacitance-current peaks after an 
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interaction is typically caused by adsorption  onto the DOPC monolayer, influencing the 
fluidity of the phospholipid layer [10].  
 
Figure 6: RCV scans, measured using the automated screening platform at a scan rate of 
40 V sA?1, of an Hg-supported DOPC monolayer (black line) and interaction with 
chlorpromazine (red line) in concentrations of (a) 10A?5 µmol dmA?3, (b) 10 µmol dmA?3 and (c) 
104 µmol dmA?3 in PBS at pH 7.4 (all RCV scans in the Supplementary Material) 
The influence of chlorpromazine concentration on the first measured capacitance-
current peak height (the peak labelled as peak A in Figure 1 and shown on the forward 
scans in Figure 6 at potentials of  ?0.96 V) is shown in Figure 7, recorded as a suppression 
of the peak after interaction with chlorpromazine, relative to an average baseline peak 
height measured for a stable DOPC monolayer. The average height of the capacitance-
current peak of the DOPC monolayer was 19.5 µA with a standard deviation of ± 1.4 µA, 
based on thirty measurements of the RCV response. The average percentage peak 
suppression is shown in Figure 7 from six measurements of chlorpromazine interaction 
for each concentration, with error bars representing the standard deviation. Results were 
compared by screening chlorpromazine using the well-validated manual system to 
demonstrate equivalence with the automated platform. The average height of the 
capacitance-current peaks of the DOPC monolayer obtained using the manual system was 
18 
 
20.9 µA ± 1.5 µA, similarly determined from an average of thirty measurements. An 
average of three measurements is shown for the chlorpromazine concentrations 
screened on the manual system, with error bars representing the standard deviation. 
More measurements were completed using the new automated platform to demonstrate 
repeatability, robustness and durability of the newly-designed platform. The average 
difference between peak suppression measured on the automated and manual system for 
all concentrations was 4%.  
 
Figure 7: Percentage suppression of first capacitance-current peak observed on the 
forward scan of RCV measurements, at a potential of approximately A?0.96 V, after 
interaction of chlorpromazine at different concentrations with an Hg-supported DOPC 
monolayer in PBS at pH 7.4, showing equivalence between the new automated platform 
and the manual predecessor biomembrane sensing system 
The automated platform dose response curve was compared with in vitro cell viability 
studies in HepG2 and A549 cells in Figure 8. The comparison was made over the range of 
concentrations from where the peak suppression became statistically significant to the 
maximum possible interaction (5 µmol dm ?3 to 100 µmol dm ?3). RCV peak suppression 
was normalised against the average maximum peak suppression recorded at 10,000 
µmol dm ?3 in Figure 7 (72%), to enable direct comparison with the cell viability studies 
(reported in a measurement range from 0 to 100%). Error bars for the cell viability 
studies show the standard deviation from three measurements. 
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Figure 8: Normalised percentage suppression of first capacitance-current peak observed 
on the forward scan of RCV measurements compared against cell viability studies of 
HepG2 and A549 cells after interaction with chlorpromazine 
A logistic function sigmoidal fit was used for both data sets in Figure 7 and Figure 8, as 
defined by Equation (1), a fitting typically used for dose response analysis, fitted with the 
Levenberg Marquardt algorithm [52]: 
 ݄ ൌ ݄ஶ ൅ ሺ݄௢ െ ݄ஶሻͳ ൅ ቀ ܿܧܥହ଴ቁ௡ (1) 
where h is the peak suppression (%), hο is the peak suppression at the highest 
concentration (%), ho is the initial peak suppression at the lowest concentration (%), c is 
the concentration of the biomembrane-active sample ȋɊ  ?3), EC50 is the 
concentration resulting in a response half way between ho and hο ȋɊ ?3) and n is a 
factor that determines the gradient of the curve. All parameters determined from the 
sigmoidal fit for the dose response curves in Figure 8 are compared in the Supplementary 
Material. The EC50  ?Ǥ ?Ɋ-3, whilst 
the HepG2 and A549 cell lines gave EC50 values   ? ? Ɋ -3 and  ? ? Ɋ -3 
respectively. Broeders et al. [53] also completed cytotoxicity studies of chlorpromazine 
interaction with human intestinal, human liver and murine fibroblast cell lines and 
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similarly reported EC50  ? ? ?Ɋ-3, dependent on the cell 
line. The phospholipid monolayer sensing technique represents a simplified mimic of a 
much more complex biological cell structure, therefore some differences between results 
could be expected. However, exceptional agreement between RCV measurements and 
cytotoxicity assays was observed. The automated RCV platform, however, achieved the 
same results in approximately 5 min, compared to 24 h required for the cytotoxicity assay 
measurements, demonstrating its suitability for robust high-throughput screening. 
 
4.3. AuNM 
To confirm the new validated screening platform was also effective for its intended 
purpose of rapid screening of nanomaterials, AuNM was screened. The RCV scans after 
the interaction of AuNM (red line) with a DOPC monolayer (black line) are shown in 
Figure 9. All RCV scans are included in the Supplementary Material. An interaction of 
AuNM with the DOPC monolayer was observed at concentrations above  ? ?Ɋ-3 of 
Au in the dispersion. No significant interactions were observed at concentrations lower 
than this. Suppression of the peaks above  ? ? Ɋ  ?3 was likely caused by AuNM 
adsorbing to the DOPC monolayer, suppressing the peaks and potentially influencing the 
fluidity of the phospholipid layer. Vakurov et al. [10] observed similar suppressed RCV 
peaks after the interaction of silica nanoparticles with a DOPC monolayer, and observed 
adsorption of the nanoparticles to the DOPC monolayer using SEM. Due to the wide range 
of properties that nanomaterials can possess, and their subsequent effect on cytotoxicity, 
direct comparison between the monolayer interactions observed in this study with 
literature studies cannot be completed easily. For example, it has been shown for both 
AuNM [51] and zinc oxide nanomaterial [5] that differences of particle size or particle 
coating can significantly influence the severity of membrane interaction. However, the 
strong agreement between RCV measurements and in vitro cytotoxicity assays observed 
for chlorpromazine in Figure 8, and a previous study comparing the interaction of silica 
nanoparticles with the monolayer-on-chip technique and unilamellar vesicles [21], gives 
credibility to the biological relevance of the electrochemical results representing 
membrane interactions observed in Figure 9. 
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Figure 9: RCV scans recorded at 40 VsA?1 of an Hg-supported DOPC monolayer (black line) 
and interaction with AuNM (red line) with a Au concentration of (a) 0.001 µmol dmA?3, (b) 
50 µmol dmA?3  and (c) 100 µmol dmA?3 in PBS at pH 7.4 (all RCV scans in Supplementary 
Material) 
The percentage peak suppression of the first capacitance-current peak on the forward 
scan after interaction of AuNM with the DOPC monolayer is shown in Figure 10. Average 
peak heights for each AuNM sample screened (six results for each concentration) are 
compared against the same baseline DOPC peak height (19.5 µA ± 1.4 µA) used for the 
chlorpromazine analysis of peak suppression, shown in Figure 7. Results from the 
automated platform were also compared with results of AuNM interaction using the older 
generation, manual system to demonstrate equivalence between the two platforms. The 
same average DOPC peak baseline (20.9 µA ± 1.5 µA) for chlorpromazine interactions, in 
Figure 7, on the manual system was used. The same concentrations of AuNM were 
screened using the manual system, with the average of three measurements reported in 
Figure 10. Error bars in Figure 10 for both sets of data represent the standard deviation of 
the peak suppression measurements. Similar results were obtained for differences 
between the peak suppressions measured on the automated platform and the manual 
system, with the average difference between results measured on both platforms equal 
to 8% peak suppression.  
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Figure 10: Percentage suppression of first capacitance-current peak observed on the 
forward scan of RCV measurements, at a potential of approximately A?0.96 V, after 
interaction of AuNM at different concentrations with an Hg-supported DOPC monolayer 
electrode in PBS at pH 7.4, showing equivalence between the new automated platform 
and the manual predecessor biomembrane sensing system 
A sigmoidal fit was used for both data sets in Figure 7, as defined by Equation (1).  ? ? ?Ɋ ?3 could not be screened due to the maximum stock 
concentration of the AuNM, therefore a value for h ? was approximated of 82.5% ± 7.5% 
to enable a logistic fit to be determined. This was estimated to be the typical maximum 
peak suppression possible, determined from chlorpromazine results in Figure 7, and RCV 
responses reported in literature using the same technique [7, 10, 28, 29]. A similar trend 
was observed between results obtained on the manual system and results obtained on 
the automated platform. However, the concentrations of AuNM for EC50 were 
approximately double on the automated platform (30 Ɋ  ?3) compared to the 
manual system (14 Ɋ ?3), potentially as a result of minor differences in flow cell 
design influencing the transport of AuNM to the sensing electrode. 
 
4.4. Viability of Platform for High-Throughput Nanomaterial Screening 
This study has presented a viable solution to rapid, high-throughput in vitro solutions for 
sensing nanomaterial-biomembrane interactions. Some of the main challenges required 
for nanomaterial screening, such as the requirements for high-throughput and 
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appropriate flow channel designs to allow the required transport of nanomaterials to 
sensing areas, discussed in Section 1, have been addressed in the new platform design, 
improving the potential for wider usage of the technique for screening nanomaterials. 
Despite being a phospholipid monolayer system, and therefore being a simplified mimic 
of a complex cell membrane structure, a strong correlation was observed for 
chlorpromazine screening on the automated RCV platform and in vitro cell viability 
studies in HepG2 and A549 cells. However, results on the automated screening platform 
were obtained in approximately 5 to 6 min per assay, whereas cell viability cytotoxicity 
results were obtained after 24 h, demonstrating the advantage of using the 
electrochemical platform for rapid screening. Some mechanistic understanding of the 
interaction was also gained, with RCV peak suppression likely to be caused by adsorption 
of the AuNM to the DOPC monolayer.  
The platform is ideally suited for investigations of membrane interaction in a range of 
experimental conditions. Different cell membrane compositions, for example, can be 
analysed through the use of multiple phospholipids, to create a mixed phospholipid 
membrane monolayer supported on Hg [35], or through the integration of cholesterol 
into the supported monolayer [34], widening the potential scope of nanomaterial-
biomembrane interaction investigations. Limitations of some cytotoxicity assays, such as 
the possibility of nanomaterial transformations in the assay, as discussed in Section 1, 
can also be avoided due to the rapid screening time, enabling a precisely controlled 
environment for screening nanomaterials. 
This work has also demonstrated important improvements to the screening technique, 
significantly increasing its viability as a high-throughput in vitro solution for 
nanomaterial screening. Throughput was significantly increased, compared to the 
predecessor system, with screening time reduced from approximately 10 min per assay 
to 5 Ȃ 6 min per assay on the new automated platform. Consumption of PBS was also 
significantly decreased by at least 50%.  Stable DOPC monolayers could be formed on the 
Pt/Hg electrode, confirmed by consistent and durable peak heights, using only 5 cm ?3 of 
DOPC, 50% less than consumed on the manual system, as a result of a smaller sensing 
volume in the new microfluidic flow cell. This also decreased the quantity of waste fluid 
from the screening. In addition to decreased fluid consumption, the screening process 
was carried out with much greater ease using the new platform, due to automation of the 
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system and the development of an easy-to-use user interface. The sensitivity of the 
electrochemically-measured results to flow rates and consumption of DOPC and PBS 
could also be investigated more thoroughly as a result of automation. Potential also exists 
to increase throughput and usability further, by automating data processing to quantify 
biomembrane activity in real-time and increasing the number of sensing modules 
integrated on to the platform.  
 
5. Conclusion 
An automated electrochemical biomembrane screening platform has been developed for 
the purpose of rapid, high-throughput screening of nanomaterial-biomembrane 
interactions. The design of the platform has been discussed, with chlorpromazine and 
AuNM assessed using the screening platform to demonstrate the performance of the 
system and its viability as a high-throughput sensor for screening nanomaterials. The 
following conclusions were reached: 
x A new screening platform was developed to enhance an existing, well-established 
technique for sensing biomembrane activity with significantly decreased operator 
skill level requirements, by automating key aspects of the screening process and 
integrating automated syringe pumps into the platform design. 
x An easy-to-use user interface was developed to control the screening platform and 
display electrochemical results, simplifying the screening process. 
x Chlorpromazine and AuNM were screened using the new platform, with both 
showing interactions with the DOPC membrane at concentrations of greater than  ?Ɋ-3. 
x A strong correlation was observed between RCV-measured biomembrane 
interaction after the interaction of chlorpromazine with the DOPC monolayer and 
routine in vitro cytotoxicity assays. 
x Decreased fluid consumption during screening was achieved by decreasing the 
volume of tubing required to transport fluids to the flow cell, by designing a new 
microfluidic flow cell and automated syringe pumps to store and control the flow 
of fluids into the flow cell, decreasing buffer and DOPC usage by approximately 
50% compared to the predecessor screening system. 
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x Screening time was reduced to <6 min per assay, significantly improving 
throughout of the technique. 
 
Supplementary Material 
See Supplementary Material for further detail on the CFD turbulence model used, the 
User Interface developed for the screening platform and for RCV scans of AuNM and 
chlorpromazine at all concentrations screened using the automated platform. 
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SUPPLEMENTARY MATERIAL 
 
 
Numerical Study of Flow Cell 
To confirm that the flow cell design was appropriate for transporting species to the 
sensing electrode, CFD simulations of fluid flow and dilute species transport through the 
flow cell were completed. Chlorpromazine, a pharmaceutical compound (screened in the 
experimental study) was modelled as a dilute species to confirm transport to the sensing 
electrode, whilst flow through the flow cell was laminar. COMSOL Multiphysics 5.3a [1] 
was used to solve a finite element discretisation of the Navier-Stokes equations for fluid 
flow to simulate laminar flow through the flow cell. Similar studies of flow behaviour 
through flow cells have been completed to confirm that no undesirable flow conditions, 
(such as flow recirculation as flow channel thickness expands) influence transport to 
sensing areas within the flow cell [2, 3]. For an incompressible, steady-state, isoviscous 
flow with no gravity effects, the continuity and momentum equations are defined as [4]:  
 ׏ ή ܝ ൌ Ͳ (2) 
 ߩሺܝ ή ׏ሻܝ ൌ െ׏݌ ൅ ߤ׏ଶܝ (3) 
where u is the flow velocity field (m/s), p is the pressure (Pa)  Ɋ is the dynamic 
viscosity (Pa·s).  
To simulate the time-dependent transport of a dilute species through an incompressible 
fluid, the advection-diffusion transport equation was solved: 
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 ߲߲ܿݐ ൌ ܦ׏ଶܿ െ ܝ ή ׏ܿ (4) 
where D is the diffusion coefficient of the dilute species. 
A three-dimensional model of the flow cell geometry was created and meshed using 
103,354 tetrahedral elements, as shown in the cross section of the flow cell in Figure 11, 
refined through a mesh sensitivity study by increasing the number of elements in the 
mesh until the minimum number of elements required to achieve a robust solution was 
determined. 
 
Figure 11: Cross-section of the 3D model of the flow cell geometry and mesh used to 
discretise the geometry, consisting of 103,354 tetrahedral elements 
The fluid flow model was solved first, prior to simulating the transport of chlorpromazine 
through the flow cell. Appropriate boundary conditions were applied to solve the fluid 
flow and transport equations:  
x A pressure boundary condition of 0 Pa was specified at the outlet of the flow cell. 
x No-slip conditions applied at the wall (all boundaries in the geometry, excluding 
the inlet and outlet) 
x A symmetry boundary condition was applied to reduce computational effort, on 
the cross section surface shown in Figure 11 
x The fluid was assumed to be water with a density of 998 kg/m3 and dynamic 
viscosity of 1 x 10 ?3 Pa·s 
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x The volumetric fluid flow rate into the flow cell was equal to 4.0 cm3 min ?1, 
equivalent to the flow rate used in experimental conditions 
x An inflow concentration of 1 mol m ?3 of the dilute species was specified at the inlet 
of the flow cell, with the initial concentration throughout the geometry set to equal 
0 mol m ?3. A zero flux boundary condition was applied at the walls. 
x The dilute species was assumed to be chlorpromazine with a diffusion coefficient 
estimated to be 2.3 x 10 ?9 m2/s, determined using the Wilke-Chang equation [5], 
Equation (5): 
 ܦ ൌ ͹ǤͶ ൈ ͳͲି଼ ሺݔܯሻ଴Ǥହܶߤܸ଴Ǥ଺  (5) 
where D is the diffusion coefficient of a solute (chlorpromazine) in a solvent (water), x is 
the association parameter for water (taken as 2.6), M is the molecular weight of 
chlorpromazine (355.33 g mol ?1), T is the temperature (293 K),  Ɋ is the dynamic viscosity 
of water (1 cP) and V is the molar volume at normal boiling point, reported to be  ? 270 cm3 mol ?1 for chlorpromazine [6]. The transport of chlorpromazine through the 
flow cell is shown in the main manuscript represented by the concentration along the 
bottom surface, to demonstrate the transport of the species to the electrode.  
 
 
User Interface 
The graphical user interface used to control the automated platform is shown in Figure 
12. 
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Figure 12: User control interface consisting of (1) pump configurations, (2) operator 
controls, (3) real-time RCV response and (4) data export controls 
 
Chlorpromazine 
The chlorpromazine compound molecular structure screened with the automated and 
manual platforms is shown in Figure 13. 
 
 
Figure 13: Chlorpromazine compound molecular structure 
 
Chlorpromazine RCV Scans 
The RCV scans for each concentration of chlorpromazine screened using the automated 
biomembrane screening platform after interaction with a DOPC membrane in Figure 6. 
The individual fitting parameters determined for the logistic fit are shown in Table 1 for 
the dose response curve based on normalised peak suppression and cell viability studies 
for chlorpromazine. 
Table 1: Comparison of the logistic sigmoidal fitting parameters defined by 
Equation (1) in the main manuscript obtained from automated RCV platform dose 
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response curves after interaction of chlorpromazine with the DOPC monolayer 
compared against HepG2 and A549 cell viability studies  
Method ho (%) h ?  (%) n EC20 
(Ɋ ? 3) 
EC50 
(Ɋ ? 3) 
EC80 
(Ɋ ? 3) 
RCV 8.4  95  2.3  3.9  7.2  13  
HepG2 100 0 3 11 17 28 
A549 84  5.2  4.1  23  32  45  
 
 
 
 
Figure 14: RCV scans, measured using the automated screening platform at a scan rate of 
40 V sA?1, of a DOPC-coated Pt/Hg electrode (black line) and interaction with 
chlorpromazine (red line) in concentrations of (a) 10A?5 µmol dmA?3, (b) 10A?4 µmol dmA?3, (c) 
10A?3 µmol dmA?3, (d) 10A?2 µmol dmA?3, (e) 10A?1 µmol dmA?3, (f) 1 µmol dmA?3, (g) 5 µmol dmA?3, 
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(h) 10 µmol dmA?3, (i) 50 µmol dmA?3, (j) 102 µmol dmA?3, (k) 103 µmol dmA?3 and (l) 104 µmol 
dmA?3 in PBS at pH 7.4 
 
 
 
 
 
 
 
 
6. AuNM RCV Scans 
The RCV scans for each concentration of AuNM screened using the automated 
biomembrane screening platform after interaction with a DOPC membrane in Figure 9. 
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Figure 15: RCV scans recorded at 40 VsA?1 of a DOPC-coated Pt/Hg electrode (black solid 
line) and interaction with AuNM (red dashed line) with a Au concentration of (a) 0.001 
µmol dmA?3, (b) 0.01 µmol dmA?3, (c) 0.1 µmol dmA?3, (d) 1 µmol dmA?3, (e) 10 µmol dmA?3, (f) 50 
µmol dmA?3 and (g) 100 µmol dmA?3 in PBS at pH 7.4 
The individual fitting parameters determined for the logistic fit are shown in Table 2 for 
the dose response curves based on peak suppression results for AuNM for both the 
manual system and automated platform. 
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Table 2: Comparison of the logistic sigmoidal fitting parameters defined by 
Equation (1) in the main manuscript obtained from the manual and 
automated platform dose response curves after interaction of 
chlorpromazine with the DOPC monolayer 
Platform ho (%) h ?  (%) n EC20 
(Ɋ ? 3) 
EC50 
(Ɋ ? 3) 
Automated  4.3 ± 1.7 84 ± 5.5 1.3 ± 0.4 30 ± 11 89 ± 18 
Manual 5.4 ± 0.3 84 ± 3.7 1.4 ± 0.2 14 ± 1.7 39 ± 6.2 
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